^
Association details:
Biomarker:MGMT unmethylation
Cancer:Glioblastoma
Drug:temozolomide (DNA synthesis inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis

Published date:
10/30/2020
Excerpt:
The median OS for patients with unmethylated GBM treated with RT/TMZ pooled from 5 phase III studies (N = 655) was 14.11 months (95% confidence interval [CI], 13.18–15.04) with a median PFS of 4.99 months (95% CI, 4.25–5.72)...TMZ should be withheld for patients with unmethylated GBM...
DOI:
https://doi.org/10.1093/noajnl/vdaa082
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma

Published date:
05/26/2022
Excerpt:
Maintenance doses of SurVaxM-Montanide plus sargramostim were thereafter administered every 12 weeks. Adjuvant TMZ was administered for at least 6 cycles, after at least the first dose of SurVaxM and beginning no sooner than 28 days after completion of chemoradiation. SurVaxM was immunogenic and produced survivin-specific CD8+ T-cells and antibody (IgG) titers in both methylated and unmethylated MGMT pts and both groups showed clinical benefit. SurVaxM represents a promising therapy for nGBM, including for those pts with unmethylated MGMT genes.
Secondary therapy:
SVN53-67/M57-KLH peptide vaccine
DOI:
10.1200/JCO.2022.40.16_suppl.2037
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549)

Published date:
05/26/2022
Excerpt:
Patients with glioblastoma harboring active MGMT enzyme have median survival of 12.7 months, compared to 21.7 months for patients with the MGMT gene promoter silenced by methylation.
Secondary therapy:
bortezomib
DOI:
10.1200/JCO.2022.40.16_suppl.TPS2081
Trial ID: